Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNITE: Odetiglucan and Mitazalimab Maintenance in Pancreatic Cancer
NCT07199764Phase 2Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of odetiglucan, mitazalimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Pennsylvania. Started Nov 2025; status: recruiting.
02
Drugs
odetiglucanmitazalimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07199764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199764.